1 / 17

HORIZONS –AMI

HORIZONS –AMI A Prospective, Multicenter Randomized Trial of Heparin Plus GPIIb/ IIIa Inhibitors vs. Bivalirudiin STEMI: Final 3-year results from the HORIZONS-AMI Trial. Stone GW et al. Lancet 2011: Published online June 13, DOI:10.1016/S0140-6736(11)60764-2. Background.

forrest-shields
Download Presentation

HORIZONS –AMI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HORIZONS –AMI A Prospective, Multicenter Randomized Trial of Heparin Plus GPIIb/IIIa Inhibitors vs. BivalirudiinSTEMI: Final 3-year results from the HORIZONS-AMI Trial Stone GW et al. Lancet 2011: Published online June 13, DOI:10.1016/S0140-6736(11)60764-2

  2. Background At 1-year in the 2x2 factorial prospective, randomized HORIZONS-AMI trial: Bivalirudin alone compared to heparin plus GPIIb/IIIa inhibitors resulted in comparable rates of MI and stent thrombosis, with significantly reduced rates of major bleeding and mortality (all-cause and cardiac) 3-year results are assessed in this report Prespecified endpoints in the pharmacology arm at 3 years included death, reinfarction, ischemia driven target lesion revascularization, stroke, and the composite of these (MACE); non-CABG major bleeding and the composite of all net adverse clinical events (NACE). Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  3. Harmonizing Outcomes with Revascularization and Stents in AMI 3602 pts with STEMI with symptom onset ≤12 hours Aspirin, thienopyridine UFH + GP IIb/IIIa inhibitor (abciximab or eptifibatide) Bivalirudin monotherapy (± provisional GP IIb/IIIa) Emergent angiography, followed by triage to… R 1:1 R 3:1 CABG – – Primary PCI Medical Rx 3006 pts eligible for stent randomization Paclitaxel-eluting TAXUS stent Bare metal EXPRESS stent Clinical FU at 30 days, 6 months, 1 year, and then yearly through 3 years; angio FU at 13 months Stone, GW N Engl J Med 2008;358:2218-30.

  4. Harmonizing Outcomes with Revascularization and Stents in AMI 3602 pts with STEMI R 1:1 UFH + GP IIb/IIIa N=1802 Bivalirudin N=1800 Randomized • • • Not true MI* • • • 28 29 1-Year FU Eligible N=1774 N=1771 22 53 26 46 • • • Withdrew • • • • • • Lost to FU • • • N=1696 1-Year FU N=1702 • • • Withdrew • • • • • • Lost to FU • • • 17 57 18 44 3-Year FU N=1628 N=1634 * Biomarkers WNL and no DS >50% by core lab determination (30 day FU only) Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  5. Pharmacology Randomization: Aspirin and Thienopyridine Use Regular* aspirin use (%) Regular* thieno. use (%) 96% 93.% 97% 93% 97% 96% 95% 94% 87% 98% 97% 97% 96% 95% 95% 93% 94% 88% 66% 68% Antiplatelet agent use (%) All P = NS 33% 26% 36% All P = NS 27% *Taken >50% of days since last visit Bivalirudin alone (n=1800) Heparin + GPIIb/IIIa(n=1802) Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  6. 3-Year Major Bleeding (non-CABG)* Bivalirudin alone (n=1800) 12 Heparin + GPIIb/IIIa (n=1802) 10.5% 10 9.4% 8 6.9% Major Bleeding (%) 6 6.0% 3-yr HR (95%CI) 4 0.64 (0.51, 0.80) P=0.0001 2 0 0 3 6 9 12 15 18 21 24 27 30 33 36 Months * Intracranial, intraocular, retroperitoneal, access site bleed requiring intervention/surgery, hematoma ≥5 cm, hgb ↓ ≥3g/dL with or ≥4g/dL w/o overt source; reoperation for bleeding; or blood product transfusion Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  7. Time in Months 3-Year Cardiac Mortality ' Time in Months Heparin + GPIIb/IIIa (n=1802) Bivalirudin alone (n=1800) 3-yr HR (95%CI) 6 0.56 (0.40, 0.80) 5.1% P=0.001 5 4 3.8% Cardiac Mortality (%) 3 2.9% 2 2.1% 1 0 0 3 6 9 12 15 18 21 24 27 30 33 36 Months Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  8. 3-Year Cardiac MortalityLandmark analysis Heparin + GP IIb/IIIa (n=1802) 5 Bivalirudin (n=1800) 30 day HR (95% CI) 0.62(0.40 – 0.96) p=0.03 4 3 year HR (95% CI) 0.490.28 –0.86 p=0.01 3 2.9% Cardiac mortality (%) 2.2% 2 1.8% 1.1% 1 0 0 3 6 9 12 15 18 21 24 27 30 33 36 Months Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  9. 3-Year Reinfarction Bivalirudin alone (n=1800) 10 Heparin + GPIIb/IIIa (n=1802) 9 8.2% 8 7 6.2% 6 Reinfarction (%) 5 4.4% 4 3 3.6% 2 1 0 0 3 6 9 12 15 18 21 24 27 30 33 36 Months 3-yr HR (95%CI) 0.76 (0.59, 0.99) P=0.04 Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  10. 3-Year ReinfarctionLandmark analysis 10 Heparin + GPIIb/IIIa (n=1802) Bivalirudin (n=1800) 9 30-day HR (95% CI) 1.07 (0.66 – 1.73) p=0.79 3-year HR (95% CI) 0.66(0.49 – 0.90) p=0.007 8 7 6.5% 6 Reinfarction (%) 5 4.4% 4 3 1.9% 2 1.8% 1 0 0 3 6 9 12 15 18 21 24 27 30 33 36 Months Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  11. 3-Year All-Cause Mortality or Reinfarction Landmark analysis Heparin + GPIIb/IIIa (n=1802) 5 Bivalirudin (n=1800) 3-year HR (95% CI) 0.72 (0.58 – 0.91) p=0.005 30-day HR (95% CI) 0.84(0.61 – 1.16) p=0.30 4 10.6% 3 7.8% All-cause mortality or reinfarction (%) 2 4.5% 3.8% 1 0 0 3 6 9 12 15 18 21 24 27 30 33 36 Months Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  12. 3-year MACE Components* *Kaplan-Meier estimates, CEC adjudicated MACE= death, reinfarction, ischemia-driven target vessel revascularization, stroke Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  13. 3-year Bleeding Endpoints Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  14. 3-Year Stent Thrombosis(ARC Definite/Probable) Bivalirudin alone (n=1611) 6 Heparin + GPIIb/IIIa (n=1591) 5.1% 5 4.5% 3.5% 4 HR (95%CI) 3 Stent Thrombosis (%) 0.89 (0.65, 1.23) 3.0% p=0.49 2 1 0 0 3 6 9 12 15 18 21 24 27 30 33 36 Months ARC= Academic Research Consortium Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  15. 3-Year Stent Thrombosis*(N=3202) *All Kaplan-Meier estimates; all CEC adjudicated ARC= Academic Research Consortium Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  16. Limitations • Open label design, but high compliance to study processes • Study applicable to patients enrolled, although there were few exclusions • Slight imbalances between baseline groups and outpatient thienopyridine use, but none of the results were altered in multivariable adjustment • Results were not adjusted for multiple comparisons and should be regarded as hypothesis-generating • 8.0% of patients in the pharmacology randomization were not available for 3-year follow-up • The impact of a comparison with heparin alone, or with higher use of radial access are not known Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

  17. Conclusions: Pharmacology Randomization • In this large-scale, prospective, randomized trial of pts with STEMI undergoing primary PCI, the initial treatment with bivalirudin alone compared to heparin plus GPIIb/IIIa inhibitors at 3 years resulted in: • A significant 36% reduction in major bleeding and a significant 24% reduction in reinfarction, with non significantly different rates of stent thrombosis, TVR and stroke • A significant 44% reduction in cardiac mortality and a 25% reduction in all-cause mortality, the latter representing 18 lives saved per 1000 patients treated with bivalirudin (NNT = 54 to save 1 life) Stone, GW Lancet 2011 Published online June 13. DOI:10.1016/S0140-6736(11)60764-2

More Related